Refining primary treatment and emphasizing secondary treatment can help mitigate the survivorship gap faced by many pediatric survivors of HL.
This study used atomic absorption spectrometry to evaluate the levels of trace metals in specimens of patients with lymphoma compared with healthy controls.
Patients with Hodgkin lymphoma who were deficient for vitamin D experienced reduced progression-free and overall survival.
Imaging mass cytometry can characterize the spatial landscape of different types of immune cells in the tumor microenvironment of tissue specimens.
The combination warrants no further study in these patients.
Continued approval may be contingent upon verification of clinical benefit in a confirmatory trial.
Researchers created a discrete event simulation model to assess the potential influence of wait time ranging from 1 to 9 months on CAR-T therapy efficacy.
Gastrointestinal-tract involvement may be a comorbid condition in patients with Waldenström macroglobulinemia.
Patients referred to the clinic were diagnosed nearly 2 weeks faster compared with historical controls.
Significant associations were found between primary central nervous system lymphoma and systemic lupus erythematosus, myasthenia gravis, and uveitis.
Of patients who experienced relapse within 6 months of frontline treatment, 17% achieved a complete response.
It is hypothesized that BAFF-R could prevent the emergence of CD19-based antigen loss.
Researchers summarized the novel techniques and models currently being developed to improve prognostication in diffuse large B-cell lymphoma.
Survivors treated with 2 different kinds of chemotherapy experienced similar general and mental health, activity limitations, and increase in risk for mortality,
Compared with white patients, Hispanic and non-Hispanic black patients had significantly poorer rates of postrelapse overall survival.
Early discontinuation of rituximab in patients with B-cell non-Hodgkin lymphoma was linked with worse survival.
In this case study, CD19-directed CAR-T therapy was effective in eliminating evidence of both underlying WM as well as transformed high grade B-cell lymphoma.
A response‐adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone appeared effective as a salvage therapy for follicular lymphoma.
The development of secondary primary malignancies in patients with diffuse large B-cell lymphoma varies in accordance with several risk factors.
Recent and upcoming case reports suggest possible cases of gluteal and other implant-associated ALCLs, raising questions about the cancer risk across all types of implants.
Improved rates of 3-year overall survival were seen in patients who were younger and who were diagnosed more recently.
Although gray zone lymphoma has distinct morphologic features, immunophenotyping can make classifying gray zone lymphoma challenging.
Risk for late-occurring thromboembolism was elevated in patients who underwent allogeneic transplantation, and risk factors varied by transplantation type.
A retrospective evaluation of patients with leukemia or lymphoma treated with CAR-T therapy determined their likelihood of experiencing refractory colitis associated with the treatment.
According to the authors, treatment of patients with Bing-Neel syndrome should involve the use of CNS-penetrating approaches.
A study of real-world patients with Waldenström macroglobulinemia revealed that ibrutinib monotherapy was linked to efficacy — but also toxicity.
A global task force makes recommendations for safe and appropriate use.
Researchers conducted a meta-analysis of studies evaluating survival outcomes with rituximab plus chemotherapy with or without autologous HSCT.
Patients with positive interim PET/CT demonstrated poorer overall and progression-free survival compared with patients with negative interim PET/CT.
Researchers did not find a significant difference in survival outcomes for high- and low-risk patients with follicular lymphoma receiving immunotherapy.
Further investigations should look at the role of acquired BCL2 mutations in venetoclax resistance.
Survivors of NHL should be offered genetic counseling.
Researchers hypothesized that overlapping characteristics between autoimmune disease and NHL could be the result of similar genetic components.
The investigational treatment was associated with a high rate of neurotoxicity.
Fewer patients who experienced late relapse received upfront rituximab compared with patients who experienced early relapse.
Antibiotic treatment with carbapenem for S. aureus infection was efficacious in patients with cutaneous T-cell lymphomas.
The use of real-world data shows promise in guiding the development of management strategies for lymphoid malignancies.
In a review article, researchers discussed how to maximize treatment efficacy while minimizing adverse effects for patients with mantle cell lymphoma.
Results from a phase 2 trial suggest that adding lenalidomide to follicular lymphoma treatment with rituximab may be efficacious.
Researchers reported follow-up data for patients with advanced-stage Hodgkin lymphoma evaluated for response with positron emission tomography scanning.
Patients with concurrent diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma were more likely to have germinal center B-cell-like DLBCL.
Both autologous and allogeneic stem cell transplantation have shown benefits in patients with relapsed follicular lymphoma, but long-term data are lacking.
Nonsense mutations in CXCR4, but not frameshift mutations, were associated with poor response compared with no mutation in CXCR4.
In addition to current obinutuzumab- and rituximab-based treatment regimens, several novel agents have received approval for follicular lymphoma treatment.
Researchers evaluated whether time to diagnosis of diffuse large B-cell lymphoma was associated with prognosis and survival.
HIV-induced regulatory B cells may inhibit T cell function through multiple mechanisms, potentially driving lymphomagenesis.
Risk for malignancy was increased in patients who underwent 2 or 3 lines of treatment compared with patients who only underwent 1 line of treatment.
Severe fatigue was more common in NHL survivors compared with the general population.
Though lymphoproliferative diseases during pregnancy can lead to complications, a host of treatment options exists.
Patients who achieved event-free survival at 24 months following diagnosis were evaluated for late relapses.
The model stratified patients into 3 risk groups based on median time to disease progression.